Convergence of nanotechnology and cardiovascular medicine: Progress and emerging prospects

Nicole Iverson, Nicole Plourde, Evangelia Chnari, Gary B. Nackman, Prabhas V. Moghe

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

Advances in the emergence of biological probes, materials, and analytical tools limited to the nanoscale size range, collectively referred to as 'nanotechnology', are increasingly being applied to the understanding and treatment of the major pathophysiological problems in cardiovascular medicine. Analytical techniques based on high-resolution microscopy and molecular-level fluorescence excitation processes capable of detecting nanoscale interactions have been used to elucidate cardiovascular pathology. Nanotechnology has also significantly impacted diagnostic intervention in cardiology, with the use of nanoparticles as contrast agents, for targeted biomedical imaging of vulnerable plaques, for detection of specific pathologic targets signaling the onset of atherosclerosis, and for tracking inflammatory events. Real-time nanoscale biosensors can be used to measure cardiovascular biomarkers, and nanopore sequencing has the potential to speed up the analysis of gene expression in cardiovascular disease. Potential therapeutic applications include the use of nanomaterials in cardiovascular devices, for delivery of drugs and bioactive molecules, or in novel technologies for reducing cholesterol accumulation and for dissolving clots.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalBioDrugs
Volume22
Issue number1
DOIs
StatePublished - 2008

Fingerprint

Nanotechnology
Nanopores
Medicine
Nanostructures
Biosensing Techniques
Cardiology
Nanoparticles
Contrast Media
Microscopy
Atherosclerosis
Cardiovascular Diseases
Biomarkers
Fluorescence
Cholesterol
Pathology
Technology
Gene Expression
Equipment and Supplies
Pharmaceutical Preparations
Therapeutics

Keywords

  • Biotechnology
  • Cardiovascular disorders
  • Nanotherapeutics

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Convergence of nanotechnology and cardiovascular medicine : Progress and emerging prospects. / Iverson, Nicole; Plourde, Nicole; Chnari, Evangelia; Nackman, Gary B.; Moghe, Prabhas V.

In: BioDrugs, Vol. 22, No. 1, 2008, p. 1-10.

Research output: Contribution to journalReview article

Iverson, Nicole ; Plourde, Nicole ; Chnari, Evangelia ; Nackman, Gary B. ; Moghe, Prabhas V. / Convergence of nanotechnology and cardiovascular medicine : Progress and emerging prospects. In: BioDrugs. 2008 ; Vol. 22, No. 1. pp. 1-10.
@article{6ae1b6f3874543169e5c6bafbf8b49c9,
title = "Convergence of nanotechnology and cardiovascular medicine: Progress and emerging prospects",
abstract = "Advances in the emergence of biological probes, materials, and analytical tools limited to the nanoscale size range, collectively referred to as 'nanotechnology', are increasingly being applied to the understanding and treatment of the major pathophysiological problems in cardiovascular medicine. Analytical techniques based on high-resolution microscopy and molecular-level fluorescence excitation processes capable of detecting nanoscale interactions have been used to elucidate cardiovascular pathology. Nanotechnology has also significantly impacted diagnostic intervention in cardiology, with the use of nanoparticles as contrast agents, for targeted biomedical imaging of vulnerable plaques, for detection of specific pathologic targets signaling the onset of atherosclerosis, and for tracking inflammatory events. Real-time nanoscale biosensors can be used to measure cardiovascular biomarkers, and nanopore sequencing has the potential to speed up the analysis of gene expression in cardiovascular disease. Potential therapeutic applications include the use of nanomaterials in cardiovascular devices, for delivery of drugs and bioactive molecules, or in novel technologies for reducing cholesterol accumulation and for dissolving clots.",
keywords = "Biotechnology, Cardiovascular disorders, Nanotherapeutics",
author = "Nicole Iverson and Nicole Plourde and Evangelia Chnari and Nackman, {Gary B.} and Moghe, {Prabhas V.}",
year = "2008",
doi = "10.2165/00063030-200822010-00001",
language = "English (US)",
volume = "22",
pages = "1--10",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Convergence of nanotechnology and cardiovascular medicine

T2 - Progress and emerging prospects

AU - Iverson, Nicole

AU - Plourde, Nicole

AU - Chnari, Evangelia

AU - Nackman, Gary B.

AU - Moghe, Prabhas V.

PY - 2008

Y1 - 2008

N2 - Advances in the emergence of biological probes, materials, and analytical tools limited to the nanoscale size range, collectively referred to as 'nanotechnology', are increasingly being applied to the understanding and treatment of the major pathophysiological problems in cardiovascular medicine. Analytical techniques based on high-resolution microscopy and molecular-level fluorescence excitation processes capable of detecting nanoscale interactions have been used to elucidate cardiovascular pathology. Nanotechnology has also significantly impacted diagnostic intervention in cardiology, with the use of nanoparticles as contrast agents, for targeted biomedical imaging of vulnerable plaques, for detection of specific pathologic targets signaling the onset of atherosclerosis, and for tracking inflammatory events. Real-time nanoscale biosensors can be used to measure cardiovascular biomarkers, and nanopore sequencing has the potential to speed up the analysis of gene expression in cardiovascular disease. Potential therapeutic applications include the use of nanomaterials in cardiovascular devices, for delivery of drugs and bioactive molecules, or in novel technologies for reducing cholesterol accumulation and for dissolving clots.

AB - Advances in the emergence of biological probes, materials, and analytical tools limited to the nanoscale size range, collectively referred to as 'nanotechnology', are increasingly being applied to the understanding and treatment of the major pathophysiological problems in cardiovascular medicine. Analytical techniques based on high-resolution microscopy and molecular-level fluorescence excitation processes capable of detecting nanoscale interactions have been used to elucidate cardiovascular pathology. Nanotechnology has also significantly impacted diagnostic intervention in cardiology, with the use of nanoparticles as contrast agents, for targeted biomedical imaging of vulnerable plaques, for detection of specific pathologic targets signaling the onset of atherosclerosis, and for tracking inflammatory events. Real-time nanoscale biosensors can be used to measure cardiovascular biomarkers, and nanopore sequencing has the potential to speed up the analysis of gene expression in cardiovascular disease. Potential therapeutic applications include the use of nanomaterials in cardiovascular devices, for delivery of drugs and bioactive molecules, or in novel technologies for reducing cholesterol accumulation and for dissolving clots.

KW - Biotechnology

KW - Cardiovascular disorders

KW - Nanotherapeutics

UR - http://www.scopus.com/inward/record.url?scp=38549178361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549178361&partnerID=8YFLogxK

U2 - 10.2165/00063030-200822010-00001

DO - 10.2165/00063030-200822010-00001

M3 - Review article

C2 - 18215086

AN - SCOPUS:38549178361

VL - 22

SP - 1

EP - 10

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 1

ER -